Johnson & Johnson (JNJ) | Stock Overview & Key Data

What is JNJ's 52-week high and low?

In the last 52 weeks, Johnson & Johnson reached a high of $251.71 (on March 2, 2026) and a low of $149.04 (on June 20, 2025).

What is the market cap and P/E ratio for JNJ?

Curious about Johnson & Johnson's size and valuation? Its market capitalization stands at 555.84B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.49, and the forward P/E (looking ahead) is 17.80.

Does JNJ pay dividends? If so, what's the yield?

Yes, Johnson & Johnson is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 2.09%, and the company has paid an average of $4.97 per share annually over the past 3 years.

Who are Johnson & Johnson's main competitors or similar companies to consider before investing?

When looking at Johnson & Johnson, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Eli Lilly and LLY	821.31B	Healthcare	Drug Manufacturers - General	38.28%	153.07%
AbbVie ABBV	351.47B	Healthcare	Drug Manufacturers - General	19.18%	64.26%
Merck & Co MRK	283.10B	Healthcare	Drug Manufacturers - General	45.70%	8.90%
Medicus Pharma MDPLD	N/A	Healthcare	Drug Manufacturers - General	N/A	N/A
Amgen AMGN	187.93B	Healthcare	Drug Manufacturers - General	20.32%	54.66%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Johnson & Johnson? (e.g., ROE, Debt/Equity)

To get a sense of Johnson & Johnson's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 32.87%, the Debt to Equity ratio from the most recent quarter is 60.50, and its Gross Profit Margin stands at 67.56%.

What is the recent revenue and earnings growth for JNJ?

Looking at Johnson & Johnson's growth, its revenue over the trailing twelve months (TTM) was $96B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.90%, and quarterly earnings saw a YoY growth of -52.40%.

How much of JNJ stock is held by insiders and institutions?

Wondering who owns Johnson & Johnson stock? Company insiders (like executives and directors) hold about 0.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 75.84%.

For more common questions about our data, please visit our About Data page.